An assessment of asthma exacerbations in pediatric patients using a long-acting B2-agonist plus inhaled corticosteroid versus an inhaled corticosteroid alone

Background: An asthma exacerbation is an anticipated sudden worsening of the disease severity, which usually does not respond to conservative therapy. The management of asthma depends on the severity of the disease symptoms, which includes an inhaled corticosteroid (ICS) and a bronchodilator. This study aimed to assess the efficacy of combining a long-acting B2-agonist (LABA) with ICS, compared to ICS alone, to reduce the incidence of asthma exacerbations in pediatric patients, diagnosed with severe persistent asthma. Methods: A retrospective analysis of the medical records was conducted for 5... Mehr ...

Verfasser: Yousif S. Alakeel
Esraa Khader
Norah Altuwayli
Shahad Alrammah
Wesam Abdel-Razaq
Dokumenttyp: Artikel
Erscheinungsdatum: 2022
Reihe/Periodikum: Saudi Pharmaceutical Journal, Vol 30, Iss 3, Pp 300-305 (2022)
Verlag/Hrsg.: Elsevier
Schlagwörter: Asthma / Asthma Exacerbations / Pediatric / LABA / SABA / Inhaled Corticosteroid / Therapeutics. Pharmacology / RM1-950
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29233846
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://doi.org/10.1016/j.jsps.2022.01.006